Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Compounded GLP-1 Guidepricing database · evidence ledger

Authors & reviewers

Kim Callender, NP, FNP-BC

Lead Clinical Reviewer

Kim Callender, FNP-BC is a board-certified family nurse practitioner and the lead clinical reviewer for Compounded GLP-1 Guide. She reviews patient-journey, clinical-workflow, and care-model content: intake quality, prescriber review processes, follow-up access, refill workflows, and support escalation. Her NPI record (1144661760) is listed in the CMS NPPES registry.

Credentials & verification

Kim Callender, NP, FNP-BC — role and verification
RoleLead Clinical Reviewer
Review scopeClinical-workflow and patient-care review: provider reviews, care-model comparisons, intake quality, follow-up access, and support testing.
NPI1144661760 — verified in the CMS National Plan & Provider Enumeration System (NPPES) registry
VerificationNPI record checked against the CMS NPPES registry as of 2026-07-20. The public NPPES taxonomy is the authoritative source for licensure and specialty.

What this reviewer signs

As lead clinical reviewer, Kim Callender, FNP-BC is the named reviewer responsible for provider reviews, care-model comparisons, and clinical-workflow content. Pages in those categories name her as the accountable clinical reviewer.

← All authors & reviewers · Publisher: US Peptides Partners LLC. This profile lists only confirmed information; nothing beyond the verified facts above is asserted. See the About page for ownership and the corrections route.